Vibostolimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Vibostolimab
- vibostolimab component of mk 7684a
- Vibostolimab component of mk-7684a
- immunoglobulin g1 anti human receptor tigit t cell immunoreceptor with ig and itim domains human mus musculus monoclonal c011 gamma 1 chain disulfide with human mus musculus monoclonal c011 kappa chain dimer
- immunoglobulin g1 kappa anti homo sapiens t cell immunoreceptor with ig and itim domains v set and immunoglobulin domain containing protein 9 v set and transmembrane domain containing protein 3 humanized monoclonal antibody gamma 1 heavy chain humanized 1 449 vh homo sapiens ighv1 69 08 85 ighd ighj3 01 93 8 8 12 1 119 homo sapiens ighg1 01 100 120 449 222 214 disulfide with kappa light chain humanized 1 214 v kappa homo sapiens igkv1 27 01 85 igkj5 01 92 6 3 9 1 107 homo sapiens igkc 01 100 108 214 dimer 228 228 231 231 bisdisulfide
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS T-CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAINS, V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING PROTEIN 9, V-SET AND TRANSMEMBRANE DOMAIN-CONTAINING PROTEIN 3)HUMANIZED MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN HUMANIZED (1-449) (VH (HOMO SAPIENS IGHV1-69*08 (85%) (IGHD)-IGHJ3*01 (93%)) (8.8.12) (1-119)-HOMO SAPIENS IGHG1*01 (100%) (120-449)) (222-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-27*01 (85%) IGKJ5*01 (92%))(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%) (108'-214')), DIMER (228-228'':231-231'')-BISDISULFIDE
- IMMUNOGLOBULIN G1, ANTI-(HUMAN RECEPTOR TIGIT (T-CELL IMMUNORECEPTOR WITH IG AND ITIM DOMAINS)) (HUMAN-MUS MUSCULUS MONOCLONAL C011 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL C011 .KAPPA.-CHAIN, DIMER
- mk 7684
- mk 7684a component vibostolimab
- Mk-7684
- MK-7684
- MK-7684A COMPONENT VIBOSTOLIMAB
- mk7684
- MK7684
- pembrolizumab vibostolimab
- t cell immunoglobulin and immunoreceptor tyrosine based inhibitory motif inhibitor mk 7684
- T-CELL IMMUNOGLOBULIN AND IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIF INHIBITOR MK-7684
- tigit inhibitor mk 7684
- TIGIT INHIBITOR MK-7684
- tigit targeting agent mk 7684
- TIGIT-TARGETING AGENT MK-7684
- vibostolimab
- Vibostolimab
- vibostolimab [INN]
- VIBOSTOLIMAB [USAN]
- Vibostolimab [WHO-DD]
- vibostolimab inn
- vibostolimab usan
And 1 more, listed on the interactive page.
- CAS registry numbers
- 2231305-30-7
- ChEMBL ID
- CHEMBL4297785
- FDA ingredient codes (UNII)
- 5XO3JF0FEK
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- T-cell immunoreceptor with Ig and ITIM domains antagonist
- Action type
- Antagonist
- Target
- T-cell immunoreceptor with Ig and ITIM domains
- Protein identifier
- Q495A1
Open Targets mechanisms
- Mechanism
- T-cell immunoreceptor with Ig and ITIM domains antagonist
- Action type
- Antagonist
- Target
- T-cell immunoreceptor with Ig and ITIM domains
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001642
- Subject identifier
- D019337
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Neoplasm Metastasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009708
- Subject identifier
- D009362
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Lung Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0021117
- Subject identifier
- D008175
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001642
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004703
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005157
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009348
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0040679
- Highest recorded phase
- 1
Reported adverse events
- Event
- microvascular coronary artery disease
- Reports
- 2
- Reporting signal score
- 21.311
- NCT02625961
- NCT02964013
- NCT04165070
- NCT04725188
- NCT04738487
- NCT05226598
- NCT05298423
- NCT04303169
- NCT04305041
- NCT04305054
- NCT05665595
- NCT04626479
- NCT04895722
- NCT05005442
- NCT05224141
- NCT05845814
- NCT06395090
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- Asn-299 $ Asn-299''''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 146-202 $ 146''-202'' $ 214'-222 $ 214'''-222'' $ 228-228'' $ 231-231'' $ 263-323 $ 263''-323'' $ 369-427 $ 369''-427''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-299 $ Asn-299''
Related records
Trials (17)
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
- A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
- A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
- Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
- Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
- Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
In development for (11)
- Colorectal cancer Phase 2
- Lung cancer Phase 3
- Lung neoplasm Phase 3
- Lymphoid neoplasm Phase 2
- Melanoma Phase 3
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 3
- Renal cell carcinoma Phase 1
- Small cell lung carcinoma Phase 3
- Urinary bladder cancer Phase 2
- Urothelial carcinoma Phase 2
Targets (1)
- TIGIT T-cell immunoreceptor with Ig and ITIM domains antagonist